Systemic sclerosis & Raynaud's
Cancer in Systemic Sclerosis: Clinical Associations and Prognostic Impact From the EUSTAR Registry
Authors' conclusion
Cancer timing and site identify distinct clinical-serologic associations in SSc, with different prognostic implications.
Study context
- Population
- Patients with systemic sclerosis (SSc) in the EUSTAR registry (mean age 55 ± 13 years; 88% female; 27.5% diffuse SSc)
- Participants
- 454 vs 454
- Comparison
- SSc patients who developed cancer vs cancer-free SSc controls
- Casesn = 454
- Controlsn = 454reference
- Outcome
- Clinical, serologic and treatment associations of cancer by timing (synchronous, subsequent, previous), and survival
Methodological detailsmatched for age and disease duration, EUSTAR registry
- Matched for age and disease duration
- EUSTAR registry
Main finding
As reported in the abstract
Associations with synchronous cancers (±3 years of SSc onset)
Odds ratio (95% CI)
Anti-POLR3
2.06(1.13–3.69)
U1RNP
3.56(1.03–12.3)
Smoking
1.57(1.01–2.44)
Digital ulcersnegative association
0.55(0.31–0.93)
Observational data: associations, not effects.
Further findings
Associations with subsequent cancers (>3 years after SSc onset)
| OR (95% CI) | ||
|---|---|---|
| CalcinosisInverse association | 0.42 (0.17–0.93) | |
| 0.10.31310Odds ratio (log scale) |
Associations with lung cancer (mainly subsequent)
| OR (95% CI) | ||
|---|---|---|
| ILD | 2.00 (1.12–3.54) | |
| Anti-topoisomerase | 2.61 (1.38–5.04) | |
| 0.20.5125Odds ratio (log scale) |
- Lung cancer also associated with smoking
Breast cancer
- Time-dependent associations with anti-POLR3 and anti-PM/Scl
Treatment and survival
- Cancers more frequent in patients treated with CYC
- Malignancy worsened overall survival, particularly when subsequent
- Radiation therapy did not impact mortality rate or new-onset interstitial lung disease (ILD)
Original publication
Cancer in Systemic Sclerosis: Clinical Associations and Prognostic Impact From the EUSTAR Registry. Arthritis Rheumatol. Published 28 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →